TW218847B - - Google Patents

Info

Publication number
TW218847B
TW218847B TW081110531A TW81110531A TW218847B TW 218847 B TW218847 B TW 218847B TW 081110531 A TW081110531 A TW 081110531A TW 81110531 A TW81110531 A TW 81110531A TW 218847 B TW218847 B TW 218847B
Authority
TW
Taiwan
Prior art keywords
conjugate
copolymer
optionally
lyophilized composition
linked
Prior art date
Application number
TW081110531A
Other languages
English (en)
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Application granted granted Critical
Publication of TW218847B publication Critical patent/TW218847B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW081110531A 1992-01-07 1992-12-31 TW218847B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929200247A GB9200247D0 (en) 1992-01-07 1992-01-07 Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation

Publications (1)

Publication Number Publication Date
TW218847B true TW218847B (zh) 1994-01-11

Family

ID=10708214

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081110531A TW218847B (zh) 1992-01-07 1992-12-31

Country Status (22)

Country Link
US (1) US6245358B1 (zh)
EP (1) EP0574571B1 (zh)
JP (1) JPH06505755A (zh)
KR (1) KR100290222B1 (zh)
AT (1) ATE179618T1 (zh)
AU (1) AU666513B2 (zh)
CA (1) CA2105466A1 (zh)
DE (1) DE69229109T2 (zh)
DK (1) DK0574571T3 (zh)
ES (1) ES2133380T3 (zh)
FI (1) FI933853A0 (zh)
GB (1) GB9200247D0 (zh)
GR (1) GR3030633T3 (zh)
HU (2) HU217806B (zh)
IL (1) IL104256A (zh)
MX (1) MX9207605A (zh)
NZ (1) NZ246577A (zh)
RU (1) RU2118171C1 (zh)
TW (1) TW218847B (zh)
UA (1) UA32522C2 (zh)
WO (1) WO1993013804A1 (zh)
ZA (1) ZA9210049B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
WO1998047496A2 (en) * 1997-04-18 1998-10-29 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US7314956B2 (en) 2001-08-08 2008-01-01 Vaxim, Inc. Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
WO2003017938A2 (en) * 2001-08-22 2003-03-06 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
MXPA05004299A (es) * 2002-10-25 2005-08-03 Pfizer Prod Inc Formulacion de liberacion prolongada de agentes activos arilheterociclicos en forma de suspension.
EA009123B1 (ru) * 2003-01-14 2007-10-26 Тева Фармасьютикал Индастриз, Лтд. Парентеральные композиции пептидов для лечения системной красной волчанки
KR20070088447A (ko) * 2005-05-11 2007-08-29 시코르, 인크. 안정한 동결건조된 안트라사이클린 글리코시드
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
JP2010516626A (ja) * 2007-01-16 2010-05-20 バイパー サイエンシズ，インコーポレイティド ガン治療剤
KR20100087002A (ko) * 2007-11-12 2010-08-02 노파르티스 아게 발사르탄을 포함하는 액체 조성물
WO2009118754A2 (en) * 2008-03-28 2009-10-01 Astron Research Limited A process for preparing a stable lyophilized composition
CA2723315A1 (en) * 2008-04-30 2009-11-05 Ben-Gurion University Of The Negev Research And Development Authority Vascular delivery systems
KR102239752B1 (ko) * 2019-12-11 2021-04-13 한국과학기술연구원 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS173846B1 (zh) * 1974-04-23 1977-03-31
US4460560A (en) * 1982-06-18 1984-07-17 University Of Southern California Drug delivery by polymeric carriers
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
FR2583983B1 (fr) * 1985-06-07 1988-05-27 Centre Nat Rech Scient Nouvelles prodrogues macromoleculaires hydrosolubles, leur preparation et leur utilisation comme medicaments notamment antitumoraux et antiparasitaires
GB8519452D0 (en) * 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
US4968742A (en) * 1987-11-09 1990-11-06 Miles Inc. Preparation of ligand-polymer conjugate having a controlled number of introduced ligands
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs

Also Published As

Publication number Publication date
ES2133380T3 (es) 1999-09-16
FI933853A (fi) 1993-09-03
NZ246577A (en) 1996-03-26
IL104256A0 (en) 1993-05-13
HUT74578A (en) 1997-01-28
ZA9210049B (en) 1993-10-06
DE69229109T2 (de) 1999-08-26
GR3030633T3 (en) 1999-10-29
HU217806B (hu) 2000-04-28
UA32522C2 (uk) 2001-02-15
RU2118171C1 (ru) 1998-08-27
HU211636A9 (en) 1995-12-28
ATE179618T1 (de) 1999-05-15
FI933853A0 (fi) 1993-09-03
HU9302517D0 (en) 1993-12-28
IL104256A (en) 1997-02-18
KR100290222B1 (ko) 2001-09-17
GB9200247D0 (en) 1992-02-26
EP0574571B1 (en) 1999-05-06
CA2105466A1 (en) 1993-07-08
EP0574571A1 (en) 1993-12-22
US6245358B1 (en) 2001-06-12
AU3346893A (en) 1993-08-03
AU666513B2 (en) 1996-02-15
MX9207605A (es) 1993-08-01
JPH06505755A (ja) 1994-06-30
DK0574571T3 (da) 1999-11-01
DE69229109D1 (de) 1999-06-10
WO1993013804A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
TW218847B (zh)
IE852593L (en) Compositions containing anthracycline glycosides
AU691476B2 (en) Injectable taxane derivative based compositions
TR200002299T2 (tr) Epotilon kompozisyonları.
MX9203072A (es) Asialoglucoproteina-agente conjugado medicinal.
GR3035501T3 (en) Peptide-carbohydrate conjugates generating t-cell immunity.
AU1179795A (en) Improved immunogenic compositions against human gastrin 17
AU9094191A (en) Recombinant avirulent salmonella antifertility vaccines
RU93055778A (ru) Фармацевтические композиции, содержащие антрациклиновые гликозиды, связанные с полимерным производным, и способ их получения
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
GR1002294B (el) Συνδυασμενο εμβολιο για streptococcus ομαδας β.
MY102186A (en) Antitumor anthracycline glycosides, their preparation intermediate thereof, and compositions and use thereof
EP1283044A3 (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
IL127851A0 (en) Inhibition of TNF activity
CA2504963A1 (en) Conjugates of tnf and a ligand of cd13 receptor in combination with interferon-gamma for treating cancer
ES2006488A6 (es) Un procedimiento para la preparacion de un glicosido de antraciclina.
AU8319491A (en) Oligosaccharide mixture, and procedure for its after-treatment
ATE252593T1 (de) Glykosidierung von 4,5-epoxymorphinan-6-olen
TW332816B (en) Peptide and carbohydrate
JPS53144570A (en) 1-osoindolinone derivatives and agriculture and horticulture containing the same as active constituents
GB1291414A (en) Aerosol composition